Blinatumomab after stem cell transplant for high-risk B-cell leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called blinatumomab, given after a stem cell transplant, to help prevent leukemia from coming back in people with high-risk B-cell acute lymphoblastic leukemia. It may help keep the cancer in remission for longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 years or older.
- You have B-cell acute lymphoblastic leukemia that is CD19 positive.
- You have had a stem cell transplant from a matched sibling, a half-matched family donor, or an unrelated donor.
- You had high-risk leukemia before the transplant, such as not reaching remission, relapsing, having high white blood cell count, or having poor genetic features.
- Your leukemia is now in complete remission, with no detectable leukemia cells, and your blood counts are good.
- You have not had severe graft-versus-host disease (GVHD) in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called blinatumomab for people whose leukemia returns in a very early, hidden way after a stem cell transplant. The goal is to see if this drug can clear those leftover leukemia cells and help keep the disease from coming back.
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
This trial tests the drug blinatumomab for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after a stem cell transplant. The goal is to see if blinatumomab can safely treat the relapse.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
This study tests a drug called blinatumomab as a maintenance treatment to help keep your leukemia in remission after a stem cell transplant. It is for people with high-risk B-cell acute lymphoblastic leukemia who have already received a transplant.
Hear when a new B-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.